0001104659-22-001638.txt : 20220105 0001104659-22-001638.hdr.sgml : 20220105 20220105194142 ACCESSION NUMBER: 0001104659-22-001638 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220103 FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoffman Michael B CENTRAL INDEX KEY: 0001290208 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39202 FILM NUMBER: 22513173 BUSINESS ADDRESS: BUSINESS PHONE: (203) 413-2200 MAIL ADDRESS: STREET 1: 1 GREENWICH OFFICE PARK CITY: GREENWICH STATE: CT ZIP: 06831 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Annovis Bio, Inc. CENTRAL INDEX KEY: 0001477845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262540421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1055 WESTLAKES DRIVE, SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 BUSINESS PHONE: 610-727-3913 MAIL ADDRESS: STREET 1: 1055 WESTLAKES DRIVE, SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 FORMER COMPANY: FORMER CONFORMED NAME: QR Pharma, Inc. DATE OF NAME CHANGE: 20091202 4 1 tm221949-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-01-03 0 0001477845 Annovis Bio, Inc. ANVS 0001290208 Hoffman Michael B C/O ANNOVIS BIO, INC. 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 1 0 1 0 Common Stock 2022-01-04 4 M 0 30000 4.39 A 1415889 D Common Stock 2022-01-04 4 F 0 6658 19.78 D 1409231 D Common Stock 2022-01-04 4 M 0 7142 0.25 A 1416373 D Common Stock 2022-01-04 4 F 0 90 19.78 D 1416283 D Stock Option (right to buy) 19.78 2022-01-03 4 A 0 9000 0 A 2032-01-03 Common Stock 9000 9000 D Stock Option (right to buy) 4.39 2022-01-04 4 M 0 30000 0 D 2020-07-01 2030-07-01 Common Stock 30000 0 D Stock Option (right to buy) 0.25 2022-01-04 4 M 0 7142 0 D 2018-04-06 2028-04-06 Common Stock 7142 0 D Reflects 6,658 shares withheld by issuer at the market price of $19.78 per share less an exercise price of $4.39 per share to fund the cashless exercise of 30,000 options. Reflects 90 shares withheld by issuer at the market price of $19.78 per share less an exercise price of $0.25 per share to fund the cashless exercise of 7,142 options. The stock option shall vest in eight consecutive quarterly installments of 1,125 shares each on the 3rd day of April, July, October and January of each year, commencing April 3, 2022, and continuing through January 3, 2024. /s/ Jeffrey McGroarty, Attorney-in-Fact for Michael Hoffman 2022-01-05